Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Looking at the rest of 2025 - part 4 of a fireside chat about Invizyne
heltzeninvestorvideo
Looking at the rest of 2025 - part 4 of a fireside chat about InvizyneFebruary 11, 2025
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
press releaseinvestor
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker SymbolFebruary 10, 2025
ARCHIVE: CEO buys IZTC stock
investorARCHIVE
ARCHIVE: CEO buys IZTC stockJanuary 21, 2025
ARCHIVE: Go To Market Strategy - part 3 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Go To Market Strategy - part 3 of a fireside chat about InvizyneJanuary 15, 2025
ARCHIVE: Using AI for Enzyme Engineering - Part 2 of a Fireside Chat About Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Using AI for Enzyme Engineering - Part 2 of a Fireside Chat About InvizyneJanuary 7, 2025
ARCHIVE: Looking back at 2024 - part 1 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Looking back at 2024 - part 1 of a fireside chat about InvizyneDecember 31, 2024
ARCHIVE: Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
biofuelpress releaseARCHIVE
ARCHIVE: Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel CapabilitiesNovember 19, 2024
ARCHIVE: Invizyne Technologies Announces Closing of Initial Public Offering
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Closing of Initial Public OfferingNovember 14, 2024
ARCHIVE: Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing
press releaseinvestorvideoARCHIVE
ARCHIVE: Invizyne’s Nasdaq IPO Marks New Era of BiomanufacturingNovember 13, 2024
ARCHIVE: Invizyne Technologies Begins Trading on NASDAQ
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Begins Trading on NASDAQNovember 13, 2024
Previous page
Page 8 of 11
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark